Literature DB >> 7913365

Study of B and T cell phenotypes in blood from patients with common variable immunodeficiency (CVID).

J Farrant1, G Spickett, N Matamoros, D Copas, M Hernandez, M North, H Chapel, A D Webster.   

Abstract

B and T cell phenotypes in peripheral blood from 71 CVID patients have been measured in a study using directly conjugated monoclonal antibodies and two colour flow cytometry. Data was compared between different patient groups (based on whether their B cells could secrete IgM or IgG in vitro) and normal donors. There was a clear correlation between abnormalities of both B and T cells and the different patient groups. There were reduced absolute numbers of circulating CD4+ T cells, particularly those of the CD4+.CD45RA+ subset, and of CD19+ B cells in those patients whose B cells failed to secrete IgM or IgG in vitro. This demonstrates an association between B cell lymphopenia, failure of B cell immunoglobulin production in vitro and T cell subset lymphopenia in CVID. It supports the view that this group of CVID patients has a disease involving T cell regulation of B cells of varying severity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913365

Source DB:  PubMed          Journal:  Immunodeficiency        ISSN: 1067-795X


  19 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  The T cell response to persistent herpes virus infections in common variable immunodeficiency.

Authors:  M Raeiszadeh; J Kopycinski; S J Paston; T Diss; M Lowdell; G A D Hardy; A D Hislop; S Workman; A Dodi; V Emery; A D Webster
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

3.  T and B lymphocyte subpopulations and activation/differentiation markers in patients with selective IgA deficiency.

Authors:  J Litzman; M Vlková; Z Pikulová; D Stikarovská; J Lokaj
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

4.  Age dependency and mutual relations in T and B lymphocyte abnormalities in common variable immunodeficiency patients.

Authors:  M Vlková; V Thon; M Sárfyová; L Bláha; A Svobodník; J Lokaj; J Litzman
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  Thymic and bone marrow output in patients with common variable immunodeficiency.

Authors:  Federico Serana; Paolo Airò; Marco Chiarini; Cinzia Zanotti; Mirko Scarsi; Micol Frassi; Vassilios Lougaris; Alessandro Plebani; Luigi Caimi; Luisa Imberti
Journal:  J Clin Immunol       Date:  2011-04-14       Impact factor: 8.317

6.  Long-term follow-up on affinity maturation and memory B-cell generation in patients with common variable immunodeficiency.

Authors:  V Ballegaard; H Permin; T L Katzenstein; H V Marquart; L Schejbel
Journal:  J Clin Immunol       Date:  2013-05-07       Impact factor: 8.317

7.  Human cytomegalovirus infection is not increased in common variable immunodeficiency.

Authors:  C G Mullighan; S J Read; A G Bird; J B Kurtz; H M Chapel; K I Welsh
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

8.  Alterations in interleukin secretion (IL-2 and IL-4) by CD4 and CD4 CD45RO cells from common variable immunodeficiency (CVI) patients.

Authors:  J M Ferrer; J Iglesias; M Hernández; N Matamoros
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

9.  T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections.

Authors:  E A L Bateman; L Ayers; R Sadler; M Lucas; C Roberts; A Woods; K Packwood; J Burden; D Harrison; N Kaenzig; M Lee; H M Chapel; B L Ferry
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

10.  Adhesion molecules in common variable immunodeficiency (CVID)--a decrease in L-selectin-positive T lymphocytes.

Authors:  I Nordøy; F Müller; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.